Lactobacillus johnsonii CJLJ103 Attenuates Scopolamine-Induced Memory Impairment in Mice by Increasing BDNF Expression and Inhibiting NF-κB Activation.
- 2018-09-28
- Journal of Microbiology and Biotechnology 28(9)
- Hae-Ji Lee
- Su-Min Lim
- Dong-Hyun Kim
- PubMed: 30111074
- DOI: 10.4014/jmb.1805.05025
Study Design
- Type
- Clinical Trial
- Population
- Mice
- Methods
- In vivo and in vitro experimental study
- Animal Study
Abstract
In the present study, we examined whether Lactobacillus johnsonii CJLJ103 (LJ) could alleviate cholinergic memory impairment in mice. Oral administration of LJ alleviated scopolamine-induced memory impairment in passive avoidance and Y-maze tasks. Furthermore, LJ treatment increased scopolamine-suppressed BDNF expression and CREB phosphorylation in the hippocampi of the brain, as well as suppressed TNF-α expression and NF-κB activation. LJ also increased BDNF expression in corticosterone-stimulated SH-SY5Y cells and inhibited NF-κB activation in LPS-stimulated microglial BV2 cells. However, LJ did not inhibit acetylcholinesterase activity. These findings suggest that LJ, a member of human gut microbiota, may mitigate cholinergic memory impairment by increasing BDNF expression and inhibiting NF-κB activation.
Keywords: BDNF; Lactobacillus johnsonii; NF-κB; memory impairment.
Research Insights
LJ treatment increased scopolamine-suppressed BDNF expression and CREB phosphorylation in the hippocampi of the brain.
- Effect
- Beneficial
- Effect size
- Moderate
Oral administration of LJ alleviated scopolamine-induced memory impairment in passive avoidance and Y-maze tasks.
- Effect
- Beneficial
- Effect size
- Moderate